Pages that link to "Item:Q8482"
← Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8482)
Jump to navigation
Jump to search
The following pages link to Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8482):
View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)- Targeting cancer stem cell pathways for cancer therapy (DOI: 10.1038/s41392-020-0110-5) (Q8449) (← links)
- Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5) (Q8462) (← links)
- Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8463) (← links)
- Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8464) (← links)
- Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8465) (← links)
- Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8466) (← links)
- Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8467) (← links)
- Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8468) (← links)
- Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8469) (← links)
- Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8470) (← links)
- Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8471) (← links)
- Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8472) (← links)
- Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5) (Q8473) (← links)
- Section 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8474) (← links)
- Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8475) (← links)
- Section 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8476) (← links)
- Section 3.2.9: Interactions between signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8477) (← links)
- Section 3.3: The microenvironment of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8478) (← links)
- Section 3.3.1: Vascular niche microenvironments and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8479) (← links)
- Section 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8480) (← links)
- Section 3.3.3: Tumor-associated macrophages and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8481) (← links)
- Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8482) (← links)
- Section 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8483) (← links)
- Section 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8484) (← links)
- Section 3.3.7: Exosomes in the TME and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8485) (← links)
- Section 4: Therapeutic targeting of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8486) (← links)
- Section 4.1: Agents targeting CSC-associated surface biomarkers in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8487) (← links)
- Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8488) (← links)
- Section 4.3: Targeting the CSC microenvironment (from DOI: 10.1038/s41392-020-0110-5) (Q8489) (← links)
- Section 4.4: CSC-directed immunotherapy (from DOI: 10.1038/s41392-020-0110-5) (Q8490) (← links)
- Section 5: Conclusions and perspectives (from DOI: 10.1038/s41392-020-0110-5) (Q8491) (← links)
- Competing interests (from DOI: 10.1038/s41392-020-0110-5) (Q8492) (← links)